In 2017, the numbers of adults with diabetes mellitus were estimated to be 425 million worldwide and over 7.2 million in Japan.
Educators (AADE), and the Endocrine Society immediately issued a joint statement that strongly repudiated the ACP guidance, 22 causing confusion among healthcare professionals. 23, 24 This controversial conclusion not only questioned the efficacy of intensive glycemic control, but rekindled the long-standing debate 25 about the usefulness of HbA1c targets in the treatment of T2D. Three problems can be identified. First, hypoglycemia and low HbA1c concentrations are associated with higher CV risk. 26 Second, the use of either conventional 27, 28 or newer antidiabetic agents 29, 30 is associated with a higher risk of heart failure. Third, recent CV outcome trials (CVOTs) have shown that drugs that lower HbA1c to similar concentrations are associated with differing CV outcomes. 31, 32 As a result, a recent survey showed that stakeholders in drug development considered HbA1c as an imperfect target. 25 In this review, we aim to assess the usefulness of HbA1c as a therapeutic target and to discuss measures that could be implemented to improve the performance of HbA1c as a therapeutic target in T2D.
| THE RELE VAN CE OF HBA1C A S A TARG E T FOR T2D THER APY

| Biological factors affecting HbA1c concentration
Glycated hemoglobin, a minor fraction of adult hemoglobin, is formed slowly and continuously by the nonenzymatic chemical modification of hemoglobin molecules. The glycation reaction is essentially irreversible, 33 and the rate of formation of HbA1c is directly proportional to the ambient glucose concentration. The concentration of HbA1c therefore reflects glycemic history, that is, the time-weighted mean glucose over the preceding 8-12 weeks, which is determined primarily by red blood cell (RBC) lifespan. 34 HbA1c
has been proven to provide a superior estimate of mean glycemia than routine determinations of blood glucose concentration. 35, 36 Therefore, the use of HbA1c is endorsed for screening and the diagnosis of diabetes, because its concentration increases well in advance of the clinical development of diabetes. 37 The International
Expert Committee recommended the use of an HbA1c ≥6.5% for the diagnosis of diabetes in 2009, 38 and this recommendation was subsequently adopted by the ADA, 39 the World Health Organization, 40 and other professional groups. 41 Glycated hemoglobin concentration can be affected by a variety of genetic, hematologic, and disease-related factors, 42, 43 but the specific effects depend on the specific hemoglobin variant or derivative and the HbA1c assay used. This is because structural variants of hemoglobin in patients with hemoglobinopathies, such as thalassemia or sickle-cell disease, interfere with some HbA1c assays. 44 Even when the effect of carbamylated hemoglobin is excluded, high HbA1c values in nondiabetic patients are still associated with chronic kidney diseases. 45, 46 Glucose-independent racial differences in HbA1c concentrations have been observed in people both with 47 and without diabetes. 48 , 49 Black people have been reported to have 0.4% (95% CI, 0.2-0.6) higher HbA1c than white people at comparable mean glucose concentrations. 49 However, the implications of this ethnic difference in HbA1c for both the diagnosis and treatment of T2D have been debated, 50, 51 and it does not appear to affect CV outcomes in people without diabetes. 52 Apart from genetic variation, the major determinants of HbA1c are conditions influencing RBC lifespan (Table 1) . 42, 53 63 This variability occurred in the absence of a known cause, such as a hemoglobinopathy. This discordance between HbA1c and mean glucose among individuals, which is referred to as the "glycation gap," 64 is consistent with the "high glycator-low glycator" hypothesis. 65 Hempe et al. 66 showed that intensive glycemic control was disproportionately associated with hypoglycemia in "high glycators," the subgroup of ACCORD participants with a high hemoglobin glycation index (observed HbA1c-predicted HbA1c). This finding suggests that it is unwise to use an
HbA1c value alone as a therapeutic goal in the absence of information regarding the relationship between HbA1c and mean glucose in each individual.
| Estimated HbA1c as an individualized therapeutic target
Most of the conditions influencing HbA1c concentration affect RBC alone, implying the application of a population mean to an individual, can be misleading. 68 CGM, using a protocol approved by the FDA in June 2018, 69 can be used to compute a mean glucose that can be compared with the patient's HbA1c. 68 The estimated HbA1c derived from CGM can be compared with the measured HbA1c to obtain an individualized hemoglobin glycation index. If this index is taken into account when management decisions are made, irrespective of the guideline used, 21, 22 superior individualized therapy for T2D can be provided.
| CONFLI C TING FIND ING S WITH REG ARD TO THE US E OF HBA1C A S A THER APEUTI C TARG E T
A major controversy in clinical T2D research is the conflicting data regarding the effects of glucose-lowering agents on CV complications. The use of HbA1c as a surrogate for macrovascular risk in patients with T2D has faced repeated challenges.
| Observational studies: the association between HbA1c and CV risk
Many observational studies have reported an association between increases in HbA1c and CV risk in patients with T2D. The United Kingdom Prospective Diabetes Study (UKPDS) 35 70 was a prospective observational study of 3642 patients with newly diagnosed T2D that were recruited between 1977 and 1991. It showed a loglinear relationship between mean HbA1c and the incidence of CV events, without a threshold. In UKPDS 35, each 1% reduction in HbA1c was associated with 14%, 12%, and 16% reductions in the relative risk (RR) of myocardial infarction, stroke, and heart failure, respectively. The EPIC-Norfolk study 71 was another prospective population study that enrolled 4662 men and 5570 women. Their In contrast to the above, other observational studies have
shown J-or U-shaped, rather than linear, relationships between
HbA1c and mortality, which may reflect the higher mortality in patients undertaking intensive glycemic control. 7 In a retrospective cohort study of 47 970 patients with T2D who had been on intensive treatment, the adjusted hazard ratio (HR) for all-cause mortality in the lowest HbA1c decile (median HbA1c 6.4%) was 1.52, and 1.79 in the highest decile (median HbA1c 10.5%), whereas the HbA1c decile with the lowest hazard had a median HbA1c of 7.5%. 72 A J-shaped curve was also identified by analyses of two US cohort studies, 52, 73 which showed an association between low HbA1c and high all-cause mortality. A meta-analysis of seven observational studies, including 147 424 participants, 74 also revealed a significant J-shaped relationship between HbA1c and all-cause mortality, implying higher risks of mortality at both high and low HbA1c concentrations.
| Intervention trials: benefits and risks of intensive glycemic control
To investigate the benefits and risks of intensive glycemic control, the ACP reviewed five large, long-term, randomized, open-label trials ( Another trial comparing Japanese patients with T2D in the standard therapy group and those in the intensive therapy group, the Japan Diabetes Optimal Integrated Treatment study for three major risk factors of cardiovascular diseases (J-DOIT3), 75 also failed to show a reduction in macrovascular events by intensive therapy.
The UKPDS involved two separate trials, UKPDS 33 and 34, which compared intensive glycemic control and conventional treatment. In the larger UKPDS 33 (n = 3867, 36% of whom had baseline retinopathy), intensive glycemic control using sulfonylureas (chlorpropamide or glibenclamide) or insulin had no significant effect on the incidences of diabetes-related death, all-cause mortality, myo- but these failed to identify causes for the higher mortality in the intensive therapy arm. However, the interindividual differences in HbA1c 66 that were observed may be able to explain the higher mortality in the intensive therapy arm of the trial, as discussed below.
The ADVANCE trial was conducted over a median of 5 years, and compared intensive treatment with standard treatment, but showed no differences in the incidences of major macrovascular events, all-cause mortality, or CV-related death. However, more severe hypoglycemic events were observed in the intensive than in the standard therapy arm (2.7% vs 1.5%; HR: 1.86, 95% CI: 1.42-2.40). In the 6-year posttrial follow-up period (ADVANCE-ON), 77 In the VADT trial, 1791 military veterans with poorly controlled T2D were randomly assigned to receive either intensive or standard glucose control. There was no significant difference between the two groups with regard to the primary outcome (HR in the intensive therapy group: 0.88, 95% CI: 0.74-1.05), any of its components, or the incidence of death from any cause. In addition, no differences were observed between the two groups with regard to microvascular complications. After nearly 10 years of follow-up, 80 patients assigned to intensive therapy had suffered from 8.6 fewer major CV events per 1000 person-years than those assigned to standard therapy, but no differences were identified in the incidences of CV death or overall survival. Nevertheless, it remains to be determined whether the response to intensive glycemic control in patients with long-standing T2D is different to that in those with newly diagnosed T2D. 
| HBA1C TARG E TS AND C V RIS K REDUC TI ON A SSO CIATED WITH NE WER G LUCOS E-LOWERING AG ENTS
The use of conventional glucose-lowering agents, such as insulin 81 and sulfonylureas, 28, 82 has been reported to be associated with higher CV risk. Rosiglitazone, which had been expected to exert cardioprotective effects, actually caused an increase in the frequency of CV events. 29, 30 This finding raised concerns about newer glucoselowering agents and led to the issue of FDA guidance requiring postapproval CVOTs. 6 Twelve CVOTs (listed in 86 more patients in the saxagliptin group were hospitalized for heart failure than in the placebo group. In the Examination of Cardiovascular
Outcomes with Alogliptin vs Standard of Care (EXAMINE), 84 among those participants without a history of heart failure at baseline, the risk of hospital admission for heart failure was significantly higher in the alogliptin group than in the placebo group. In response to these findings, the FDA added a heart failure warning, not only to alogliptin and saxagliptin labels in April 2016, 97 . In another study, 105 which aimed to determine the effect of liraglutide on left ventricular function in chronic heart failure patients with and without T2D, treatment with liraglutide was associated with a higher heart rate and more serious cardiac adverse events.
| CON CLUS ION
The results of recent clinical trials call into question the validity of HbA1c as a therapeutic target for T2D. UKPDS showed that metformin, but not other conventional glucose-lowering agents, reduces CV risk despite similar levels of glycemic control. Rosiglitazone, which had been approved on the basis of its effect to reduce HbA1c, was found to be associated with heart failure, even when glycemic control was good. In the ACCORD, ADVANCE, VADT, and J-DOIT3 trials, the failure of intensive glycemic control to reduce CV risk again brought into question the usefulness of HbA1c as a therapeutic target in T2D. The recent CVOTs, in which glycemic control was found to be comparable between the test drug and placebo groups,
showed that the use of three newer glucose-lowering agents is associated with greater risks of heart failure or amputation, whereas others are associated with lower CV risk. These findings have offered an opportunity to reevaluate the use of HbA1c as a surrogate for mean blood glucose concentration in T2D treatment. To determine the effect of interindividual variation in hemoglobin glycation on its use as a therapeutic target in T2D, the use of individual HbA1c estimated using mean glucose values determined by CGM should be validated and applied to the outcome of clinical trials and in practice.
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